Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
The APDN news archive on Stock Titan covers the historical disclosures and announcements of Applied DNA Sciences, Inc., a biotechnology company that developed and commercialized polymerase chain reaction (PCR)-based technologies for DNA production and detection and later adopted a BNB-focused digital asset treasury strategy. During the period when it traded under the Nasdaq symbol APDN, the company issued news on operational restructuring, platform development, customer activity, and capital markets transactions.
Readers can review company updates describing the transition to a pure play provider of synthetic DNA and mRNA manufacturing solutions through its majority-owned subsidiary LineaRx, Inc., including the focus on its LineaDNA, LineaRNAP, and LineaIVT platforms. News items detail workforce reductions, the exit from DNA tagging and security products and services, the closure of Applied DNA Clinical Labs, and the consolidation of operations behind LineaRx to support advanced biotherapeutics and diagnostic applications.
The archive also includes announcements related to conference participation and scientific posters showcasing the LineaDNA and LineaIVT platforms, follow-on orders for LineaDNA from a global in vitro diagnostics manufacturer for use in a cancer diagnostic application, and engagements with mRNA-focused contract development and manufacturing organizations. Financial news covers quarterly results, non-GAAP metrics such as Adjusted EBITDA and monthly net cash burn, and commentary on cost optimization and capital allocation.
Later APDN news releases document the company’s initiation of a BNB-focused digital asset treasury strategy, private placement commitments to fund BNB acquisitions, and the planned change of its Nasdaq ticker from APDN to BNBX to reflect this strategic focus. These items describe agreements with Cypress LLC and Cypress Management LLC for digital asset management and advisory services, as well as the involvement of institutional and crypto-native investors. By following this archive, investors can trace how APDN evolved from a biotechnology-focused issuer into BNB Plus Corp. (BNBX) with a combined profile in nucleic acid production and digital asset treasury management.
Applied DNA Sciences (NASDAQ:APDN) has announced it will release its Q2 FY2025 financial results on May 15, 2025, after U.S. market close. The company will file its Form 10-Q concurrently. Following its Annual Meeting of Stockholders on May 22, Applied DNA will host an intra-quarter investor update call on June 3, 2025, at 4:30 p.m. ET, where management will discuss strategic priorities.
The conference call will be accessible via multiple channels, including domestic (844-887-9402), international (412-317-6798), and Canadian (866-605-3852) dial-in numbers. A webcast replay will be available for 7 days following the call, with access codes provided for different regions.
Applied DNA Sciences' (NASDAQ:APDN) subsidiary LineaRx has completed its transition to a U.S.-based supply chain for critical input materials used in its LineaDNA™ and LineaIVT™ platforms. This strategic move, responding to the 2024 BIOSECURE Act and customer demand, positions the company to support the reshoring of biopharmaceutical manufacturing operations in the United States.
As the largest PCR-based cell-free DNA producer in the U.S., LineaRx now sources over 75% of its manufacturing cost components domestically, including DNA template materials and manufacturing enzymes. The company's proprietary PCR-based platform enables rapid production of high-fidelity, cell-free DNA in quantities from milligram to multi-gram scale for genetic medicines development.
Applied DNA Sciences (NASDAQ:APDN) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, which specializes in PCR-based DNA technologies, received confirmation from Nasdaq's Listing Qualifications Department on April 7, 2025.
The company had previously fallen out of compliance on November 12, 2024, when it failed to maintain the required minimum bid price of $1.00 over 30 consecutive business days. To rectify this situation, APDN needed to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
The company exceeded this requirement by maintaining the minimum bid price for 16 consecutive business days, from March 14 through April 4, 2025. With this achievement, Nasdaq has confirmed the matter is now closed.
Applied DNA Sciences (NASDAQ:APDN) is repositioning its TR8™ PGx pharmacogenomics testing service to focus on specific use cases, starting with pre-emptive testing for DPYD gene variants. This initiative follows an FDA safety announcement regarding patients with DPYD genetic variants who may experience severe toxicities when taking fluoropyrimidine-based cancer drugs.
The company's TR8 PGx test, approved by the New York State Department of Health, can identify individuals with DPYD genotypes affecting DPD enzyme activity, important for metabolizing drugs like capecitabine and fluorouracil (5-FU). These medications, with approximately 924,000 prescriptions in 2022, are commonly used in treating various cancers including colorectal, breast, and cervical.
Statistics show that about 1 in 1,000 patients carry two DPYD gene variants causing DPD enzyme absence, while 3-8% of the population has one variant resulting in lower enzyme levels, with higher frequency in African Americans.
Applied DNA Sciences (NASDAQ:APDN) has submitted a validation package to the New York State Department of Health for approval of its laboratory-developed test (LDT) for detecting H5 bird flu. The company's Linea™ Avian Influenza H5 Dx assay (AIH5 Dx) is designed to detect and differentiate between pan-influenza A and H5 bird flu.
The development was initiated in January 2025 following increased concerns about H5 bird flu spread in dairy cows and poultry, along with human infections in U.S. workers. If approved, Applied DNA Clinical Labs (ADCL) will launch a testing service accepting samples from states recognizing New York's CLEP/CLIA certification.
The testing would be conducted at ADCL, an NYSDOH CLEP-permitted, CLIA-certified laboratory, adding to its existing diagnostic testing menu that includes mpox, SARS-CoV-2, and pharmacogenetic testing. The timeline for NYSDOH's review and potential approval remains uncertain.
Applied DNA Sciences (NASDAQ:APDN) has announced a 1-for-50 reverse stock split effective March 14, 2025. The split will reduce outstanding shares from approximately 55.2 million to 1.1 million, while maintaining trading on the Nasdaq Capital Market under the same symbol 'APDN'.
The reverse split follows stockholder approval granted on September 30, 2024, authorizing the Board to implement a split ratio between 1-for-5 and 1-for-50. The Board approved the maximum ratio on March 3, 2025, aiming to comply with Nasdaq's $1.00 minimum bid price requirement for continued listing.
The company will adjust proportionally all outstanding stock options, restricted stock units, and warrants. Fractional shares will be rounded up to the nearest whole share, and the $0.001 par value per share will remain unchanged.
Applied DNA Sciences (NASDAQ:APDN) reported Q1 fiscal 2025 financial results, announcing strategic restructuring initiatives. The company is exiting its DNA Tagging and Security Products business segment and implemented a 20% workforce reduction in January, expected to reduce annual payroll costs by 13% with one-time separation costs of $300,000.
Key financial highlights include revenue of $1.2 million (up 34% YoY), operating loss of $3.0 million, and net loss of $2.7 million. Cash position stands at $9.3 million as of December 31, 2024.
The company completed its GMP Site 1 facility in Stony Brook, NY, with an initial manufacturing capacity of approximately ten grams per annum, supporting potential annual revenues of $10-30 million. The facility received commercial operation certification in January 2025 and enables enzymatic manufacture of Linea DNA™ IVT templates for mRNA clinical trial materials.
Applied DNA Sciences (NASDAQ:APDN) has announced it will release its first quarter fiscal 2025 financial results after market close on Thursday, February 13, 2025. The company will host a conference call and webcast for shareholders and investors at 4:30 p.m. ET on the same day.
The conference call will be accessible via multiple channels including domestic toll-free, international, and Canadian toll-free numbers. A live webcast will be available, and an accompanying slide presentation will be embedded in both live and replay formats. A replay of the conference call will be available for 7 days following the event through various access numbers with the replay access code 7896562.